Ferri, Nicola http://orcid.org/0000-0001-8898-7441
Ruscica, Massimiliano
Santos, Raul D.
Corsini, Alberto
Funding for this research was provided by:
Università degli Studi di Padova
Article History
Accepted: 18 August 2023
First Online: 16 September 2023
Declarations
:
: NF: Consulting fees and lecture fees from Daiichi-Sankyo, Relmada Therapeutics, Recordati S.p.A., Pfizer, Pharmanutra S.p.A. MR: Fees from Alpha Sigma and Bruno Farmaceutici. RDS: Consulting fees and lecture fees from Abbott, Amgen, Amryt, AstraZeneca, Aché, Biolab, Getz Pharma, Eli-Lilly, Libbs, Merck, PTC Therapeutics, Novo Nordisk, Novartis, Sanofi-Regeneron Pharmaceuticals; grant support from Amgen, Kowa, Esperion, Novartis, Sanofi-Regeneron Pharmaceuticals. AC: Consulting fees and lecture fees from Algorithm, Amarin, Amgen, DOC, Fidia, Novartis, Recordati Spa, Sanofi, Servier; Viatris: grant support from Daiichi-Sankyo.
: This article does not contain any studies with human or animal subjects performed by any of the authors.